leflunomide has been researched along with Atopic Hypersensitivity in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When uridine was added to the cell culture, this molecule's effect on cell proliferation was completely restored, whereas the antibody production was partially restored." | 1.30 | Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. ( Amano, Y; Kitagawa, H; Mizushima, Y; Ogata, K, 1999) |
| "When leflunomide was administered both at the time of primary and subsequent immunizations, reductions in total and specific serum IgE levels of > 80% and > 38%, respectively, were observed (P < 0." | 1.30 | Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. ( Bartlett, RR; Jarman, ER; Kuba, A; Montermann, E; Reske-Kunz, AB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Pierro, F | 1 |
| d'Atri, G | 1 |
| Marcucci, F | 1 |
| Leoni, F | 1 |
| Mizushima, Y | 1 |
| Amano, Y | 1 |
| Kitagawa, H | 1 |
| Ogata, K | 1 |
| Jarman, ER | 1 |
| Kuba, A | 1 |
| Montermann, E | 1 |
| Bartlett, RR | 1 |
| Reske-Kunz, AB | 1 |
3 other studies available for leflunomide and Atopic Hypersensitivity
| Article | Year |
|---|---|
Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs.
Topics: Animals; C-Reactive Protein; Cyclosporine; Drug Evaluation, Preclinical; Female; Hypersensitivity, D | 1997 |
Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.
Topics: Administration, Oral; Aniline Compounds; Animals; Antibody Specificity; Crotonates; Disease Models, | 1999 |
Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Allergens; Animals; Antibody Formation; Down-Regulation; | 1999 |